keyword
MENU ▼
Read by QxMD icon Read
search

chemotherapy induced anaemia

keyword
https://www.readbyqxmd.com/read/28438219/adverse-drug-reactions-and-kinetics-of-cisplatin-excretion-in-urine-of-patients-undergoing-cisplatin-chemotherapy-and-radiotherapy-for-head-and-neck-cancer-a-prospective-study
#1
Marília Berlofa Visacri, Eder de Carvalho Pincinato, Graziele Baldan Ferrari, Júlia Coelho França Quintanilha, Priscila Gava Mazzola, Carmen Silvia Passos Lima, Patricia Moriel
BACKGROUND: Cisplatin is a high-potency anticancer agent; however, it causes significant adverse drug reactions (ADRs). Potential pharmacokinetic markers must be studied to predict or prevent cisplatin-induced ADRs and achieve better prognosis. This study was designed to investigate the relationship between ADRs and kinetics of cisplatin excretion in the urine of patients undergoing high-dose cisplatin chemotherapy and radiotherapy for head and neck cancer. METHODS: Outpatients with head and neck cancer received a first cycle of high-dose cisplatin chemotherapy (80-100 mg/m(2)) concurrent to radiotherapy...
April 24, 2017: Daru: Journal of Faculty of Pharmacy, Tehran University of Medical Sciences
https://www.readbyqxmd.com/read/28395880/treatment-of-metastatic-uveal-melanoma-with-adoptive-transfer-of-tumour-infiltrating-lymphocytes-a-single-centre-two-stage-single-arm-phase-2-study
#2
Smita S Chandran, Robert P T Somerville, James C Yang, Richard M Sherry, Christopher A Klebanoff, Stephanie L Goff, John R Wunderlich, David N Danforth, Daniel Zlott, Biman C Paria, Arvind C Sabesan, Abhishek K Srivastava, Liqiang Xi, Trinh H Pham, Mark Raffeld, Donald E White, Mary Ann Toomey, Steven A Rosenberg, Udai S Kammula
BACKGROUND: Uveal melanoma is a rare tumour with no established treatments once metastases develop. Although a variety of immune-based therapies have shown efficacy in metastatic cutaneous melanoma, their use in ocular variants has been disappointing. Recently, adoptive T-cell therapy has shown salvage responses in multiple refractory solid tumours. Thus, we sought to determine if adoptive transfer of autologous tumour-infiltrating lymphocytes (TILs) could mediate regression of metastatic uveal melanoma...
April 7, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28332724/efficacy-and-safety-of-biosimilar-epoetin-alpha-in-patients-with-chronic-lymphoid-neoplasms-and-chemotherapy-induced-anaemia-an-observational-retrospective-monocentric-analysis
#3
Alessandro Broccoli, Lisa Argnani, Vittorio Stefoni, Letizia Gandolfi, Pier Luigi Zinzani
Epoetin biosimilars are an alternative to originator erythropoietic agents in the treatment of chemotherapy-induced anaemia; however, their effects in patients with lymphoproliferative disorders remain unclear. This analysis examined the response of patients with lymphoproliferative disorders experiencing chemotherapy-induced anaemia to 4- or 8-week treatment with the biosimilar epoetin alpha. Treatment was initiated at first occurrence of haemoglobin (Hb) < 10 g/dL during chemotherapy and was stopped when Hb was >11 g/dL, when chemotherapy was completed, or in case of transfusion dependency...
March 23, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28203295/management-of-anaemia-in-oncohaematological-patients-treated-with-biosimilar-epoetin-alfa-results-of-an-italian-observational-retrospective-study
#4
Giovanni Rosti, Mario Petrini, Alberto Bosi, Piero Galieni, Daniele Bernardi, Gianfranco Giglio, Laura Dorotea, Brunangelo Falini, Elvira Scelzi, Enzo Veltri, Roberto Castelli, Chiara Longagnani, Tommaso Raggi, Federico Simonetti
BACKGROUND: Many patients with solid tumours or nonmyeloid haematopoietic tumours develop symptomatic anaemia, which has a major impact on quality of life (QoL). The efficacy of erythropoiesis-stimulating agents (ESAs) in improving QoL and reducing blood transfusions has been widely demonstrated. Binocrit® (biosimilar epoetin alfa) is an ESA indicated in the European Union for treating chemotherapy-induced anaemia. The aim of this study was to investigate the effect of Binocrit® on haemoglobin (Hb) levels in anaemic cancer patients in Italian clinical practice...
January 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/27956157/ibrutinib-for-patients-with-rituximab-refractory-waldenstr%C3%A3-m-s-macroglobulinaemia-innovate-an-open-label-substudy-of-an-international-multicentre-phase-3-trial
#5
Meletios A Dimopoulos, Judith Trotman, Alessandra Tedeschi, Jeffrey V Matous, David Macdonald, Constantine Tam, Olivier Tournilhac, Shuo Ma, Albert Oriol, Leonard T Heffner, Chaim Shustik, Ramón García-Sanz, Robert F Cornell, Carlos Fernández de Larrea, Jorge J Castillo, Miquel Granell, Marie-Christine Kyrtsonis, Veronique Leblond, Argiris Symeonidis, Efstathios Kastritis, Priyanka Singh, Jianling Li, Thorsten Graef, Elizabeth Bilotti, Steven Treon, Christian Buske
BACKGROUND: In the era of widespread rituximab use for Waldenström's macroglobulinaemia, new treatment options for patients with rituximab-refractory disease are an important clinical need. Ibrutinib has induced durable responses in previously treated patients with Waldenström's macroglobulinaemia. We assessed the efficacy and safety of ibrutinib in a population with rituximab-refractory disease. METHODS: This multicentre, open-label substudy was done at 19 sites in seven countries in adults aged 18 years and older with confirmed Waldenström's macroglobulinaemia, refractory to rituximab and requiring treatment...
February 2017: Lancet Oncology
https://www.readbyqxmd.com/read/27855097/combination-with-intravenous-iron-supplementation-or-doubling-erythropoietin-dose-for-patients-with-chemotherapy-induced-anaemia-inadequately-responsive-to-initial-erythropoietin-treatment-alone-study-protocol-for-a-randomised-controlled-trial
#6
Lin Chen, Hong Jiang, Wei Gao, Ye Tu, Ying Zhou, Xi Li, Zhe Zhu, Qixin Jiang, Haifeng Zhan, Jiangming Yu, Chuangang Fu, Yong Gao
INTRODUCTION: Erythropoietin (EPO) is a commonly used option in the treatment of chemotherapy-induced anaemia (CIA). However, ∼30-50% of patients fail to achieve an adequate response after initial treatment. Prior studies have demonstrated that intravenous iron might synergistically improve therapeutic response to EPO treatment in this patient population. METHODS AND ANALYSIS: We will perform this multicentre, randomised, open-label, parallel-group, active controlled non-inferiority study to compare the two combination therapies of EPO plus intravenous iron regimen versus doubling the dose of EPO in patients with CIA who have an inadequate response to initial EPO treatment at a routine dose...
October 7, 2016: BMJ Open
https://www.readbyqxmd.com/read/27699026/clinical-and-imaging-characteristics-of-53-ulcers-of-post-radiation-nasopharyngeal-necrosis-in-patients-with-nasopharyngeal-carcinoma
#7
Fengqin Yan, Zhimin Ye, Fangzheng Wang, Lei Wang, Weiyang Li, Zhenfu Fu
It is widely accepted that a mucosal ulcer induced by radiation (RIMU) is the predominant type of post-radiation nasopharyngeal ulcer in patients with nasopharyngeal carcinoma (NPC) who underwent radiotherapy (RT); however, another type of ulcer, an ulcer of post-radiation nasopharyngeal necrosis (UPRNN), has rarely been reported for patients with NPC. In the present study, the clinical and imaging features of 53 patients who were treated at the Zhejiang Provincial Cancer Center (Zhejiang Cancer Hospital, Hangzhou, China) between March 2009 and December 2015, and who were diagnosed with UPRNN, were reviewed...
October 2016: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/27206325/risk-of-venous-thromboembolism-in-cancer-patients-treated-with-epoetins-or-blood-transfusions
#8
Antonios Douros, Kathrin Jobski, Bianca Kollhorst, Tania Schink, Edeltraut Garbe
AIMS: Anaemia is common in cancer patients, with treatments including epoetins and blood transfusions. Although an increased risk of venous thromboembolism (VTE) has been associated with both therapeutics, studies comparing the risk of VTE between epoetins and transfusions in cancer patients are lacking. METHODS: A nested case-control study investigated this risk using the German Pharmacoepidemiological Research Database. Cohort members were incident cancer patients receiving first time treatment with epoetin or transfusion...
September 2016: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/26907163/the-effectiveness-and-cost-effectiveness-of-erythropoiesis-stimulating-agents-epoetin-and-darbepoetin-for-treating-cancer-treatment-induced-anaemia-including-review-of-technology-appraisal-no-142-a-systematic-review-and-economic-model
#9
REVIEW
Louise Crathorne, Nicola Huxley, Marcela Haasova, Tristan Snowsill, Tracey Jones-Hughes, Martin Hoyle, Simon Briscoe, Helen Coelho, Linda Long, Antonieta Medina-Lara, Ruben Mujica-Mota, Mark Napier, Chris Hyde
BACKGROUND: Anaemia is a common side effect of cancer treatments and can lead to a reduction in quality of life. Erythropoiesis-stimulating agents (ESAs) are licensed for use in conjunction with red blood cell transfusions to improve cancer treatment-induced anaemia (CIA). OBJECTIVE: To investigate the effectiveness and cost-effectiveness of ESAs in anaemia associated with cancer treatment (specifically chemotherapy). DATA SOURCES: The following databases were searched from 2004 to 2013: The Cochrane Library, MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, Web of Science, Cumulative Index to Nursing and Allied Health Literature, British Nursing Index, Health Management Information Consortium, Current Controlled Trials and ClinicalTrials...
February 2016: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/26744538/pathophysiology-of-tumour-induced-microangiopathic-haemolytic-anaemia
#10
Pavani Chalasani, Jennifer M Segar, Marilyn Marron, Alison Stopeck
Cancer-associated microangiopathic haemolytic anaemia (CA-MAHA) is a syndrome characterised by Coombs-negative haemolytic anaemia and thrombocytopenia. It is primarily seen in advanced solid tumours and is distinct from thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome. Diagnosis is often delayed and patients have a high mortality. We present the case of CA-MAHA in a patient with metastatic breast cancer treated successfully with early initiation of chemotherapy. In addition, we report longitudinal laboratory evaluation of circulating tumour cells and microparticles and suggest a hypothesis for the mechanism behind CA-MAHA...
January 7, 2016: BMJ Case Reports
https://www.readbyqxmd.com/read/26578732/pre-treatment-lymphocytopaenia-is-an-adverse-prognostic-biomarker-in-muscle-invasive-and-advanced-bladder-cancer
#11
N Joseph, S J Dovedi, C Thompson, J Lyons, J Kennedy, T Elliott, C M West, A Choudhury
BACKGROUND: Pre-treatment lymphocytopaenia may result from cytokines secreted by the tumour microenvironment in association with aggressive tumour biology. We sought to establish the prognostic significance of lymphocytopaenia in muscle-invasive and advanced bladder cancer. PATIENTS AND METHODS: Seventy-four patients with muscle-invasive bladder cancer treated with radical chemoradiotherapy and 131 patients with advanced bladder cancer treated with palliative chemotherapy were included in the study...
February 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/26426164/biosimilar-epoetin-zeta-in-oncology-and-haematology-development-and-experience-following-6-years-of-use
#12
REVIEW
Mauricette Michallet, Christoph Losem
Chemotherapy-induced anaemia is frequent in cancer patients, with severity depending on the extent of the disease and intensity of treatment. Clinical guidelines recommend erythropoietin therapy to treat or prevent anaemia in some oncology/haematology patients being treated with chemotherapy. The patent expiry of the first-generation erythropoietins has led to the development of biosimilar products, i.e. therapeutic proteins exhibiting comparable quality, safety and efficacy to an existing reference biological medicine, the patent of which has expired...
2016: Acta Haematologica
https://www.readbyqxmd.com/read/26272769/safety-and-efficacy-of-rolapitant-for-prevention-of-chemotherapy-induced-nausea-and-vomiting-after-administration-of-cisplatin-based-highly-emetogenic-chemotherapy-in-patients-with-cancer-two-randomised-active-controlled-double-blind-phase-3-trials
#13
RANDOMIZED CONTROLLED TRIAL
Bernardo L Rapoport, Martin R Chasen, Cesare Gridelli, Laszlo Urban, Manuel R Modiano, Ian D Schnadig, Allen Poma, Sujata Arora, Vikram Kansra, Lee S Schwartzberg, Rudolph M Navari
BACKGROUND: Highly emetogenic chemotherapy induces emesis in almost all patients in the absence of prophylaxis. Guidelines recommend use of a neurokinin-1 (NK-1) receptor antagonist in conjunction with a 5-HT3 receptor antagonist and corticosteroid in patients receiving highly emetogenic chemotherapy. We aimed to assess rolapitant, an NK-1 receptor antagonist, for prevention of chemotherapy-induced nausea and vomiting in patients with cancer after administration of cisplatin-based highly emetogenic chemotherapy...
September 2015: Lancet Oncology
https://www.readbyqxmd.com/read/26232556/erythropoietin-protects-neuroblastoma-cells-against-etoposide-and-vincristine-by-activating-erk-and-akt-pathways-but-has-no-effect-in-kidney-cells
#14
Maria Jose Vazquez-Mellado, Cecilia Aguilar, Leticia Rocha-Zavaleta
AIMS: Chemotherapy induces anaemia in neuroblastoma patients. Cancer-associated anaemia may be treated with recombinant erythropoietin. However, the potential effects of erythropoietin on neuroblastoma and kidney cells have not been extensively evaluated. The present study was designed to investigate the effect of erythropoietin on the proliferation, and protection against vincristine- and etoposide-induced cell death in neuroblastoma (MSN), and embryonic kidney (HEK 293) cells. MAIN METHODS: The expression of erythropoietin and its receptor in MSN and HEK 293 was analysed by RT-PCR, immunocytochemistry, and Western blotting...
September 15, 2015: Life Sciences
https://www.readbyqxmd.com/read/26011836/the-configuration-of-biomolecular-markers-in-cancer-of-the-uterine-cervix-personalized-therapy-monitoring-and-prognosis
#15
V M Prunoiu, M A Marincaş, C Cirimbei, S Ionescu, S Zurac, M Radu, R Nicolaescu, E Brătucu, N D Straja
INTRODUCTION: The paper deals with the diagnosis of some aggressive forms of uterine cervix cancers, resistant to radio chemotherapy, using biomolecular markers.For this study, the destruction of tumours in stages II-IIIBis carried out by hyperthermia induced by different sources of energy. The aimed targets are toembed a quick and simple technique of haemostas isused in bleeding uterine cervix tumours associated with acute an aemiain the treatment protocols and to identify biomolecular criteria revealing tumour aggressiveness and treatment response...
March 2015: Chirurgia
https://www.readbyqxmd.com/read/25943156/origins-and-implications-of-neglect-of-g6pd-deficiency-and-primaquine-toxicity-in-plasmodium-vivax-malaria
#16
REVIEW
Kevin Baird
Most of the tens of millions of clinical attacks caused by Plasmodium vivax each year likely originate from dormant liver forms called hypnozoites. We do not systematically attack that reservoir because the only drug available, primaquine, is poorly suited to doing so. Primaquine was licenced for anti-relapse therapy in 1952 and became available despite threatening patients having an inborn deficiency of glucose-6-phosphate dehydrogenase (G6PD) with acute haemolytic anaemia. The standard method for screening G6PD deficiency, the fluorescent spot test, has proved impractical where most malaria patients live...
May 2015: Pathogens and Global Health
https://www.readbyqxmd.com/read/25899311/olaparib-a-review-of-its-use-as-maintenance-therapy-in-patients-with-ovarian-cancer
#17
REVIEW
James E Frampton
Olaparib (Lynparza™) is a first-in-class, orally-active, small molecule, poly (ADP-ribose) polymerase inhibitor that induces synthetic lethality in homozygous BRCA-deficient cells. In the EU, the capsule formulation of olaparib is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive, relapsed, BRCA-mutated (germline and/or somatic), high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy...
April 2015: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/25893427/risk-evaluation-mitigation-strategy-impact-of-application-of-the-food-and-drug-adminstration-s-strategy-on-use-of-erythropoiesis-stimulating-agents-and-transfusion-in-patients-with-chemotherapy-induced-anaemia
#18
K Hollingsworth, M C Romney, A Crawford, J McAna
WHAT IS KNOWN AND OBJECTIVE: The Food and Drug Administration (FDA) instituted a risk evaluation mitigation strategy (REMS) for erythropoiesis-stimulating agent (ESA) use in patients with cancer in February 2010. Implementation of REMS was considered likely to reduce ESA use and increase red blood cell transfusions. We aimed to quantify ESA and transfusion use pre- and post-REMS. METHODS: A retrospective data analysis was conducted using the Medicare 5% Sample Database from 2008 through 2011...
June 2015: Journal of Clinical Pharmacy and Therapeutics
https://www.readbyqxmd.com/read/25872413/severe-and-fatal-adverse-events-risk-associated-with-rituximab-addition-to-b-cell-non-hodgkin-s-lymphoma-b-nhl-chemotherapy-a-meta-analysis
#19
REVIEW
Qingling Hua, Yanzhe Zhu, Hu Liu
PURPOSE: Rituximab is a monoclonal antibody targetting the CD20 antigen with the ability to increase overall remission (OR) in B-cell non-Hodgkin's lymphoma (B-NHL). A systematic review and meta-analysis were conducted to determine the risk of the most clinically relevant severe and fatal adverse events (AEs) associated with the use of rituximab in the treatment of B-NHL. PATIENTS AND METHODS: We included phase III clinical trials that used chemotherapy in combination with rituximab or chemotherapy alone as for B-NHL...
2015: Journal of Chemotherapy
https://www.readbyqxmd.com/read/25841398/the-latest-meta-analysis-on-the-use-of-erythritopoiesis-stimulating-agents-in-chemotherapy-induced-anaemia-brings-new-light-on-the-safety
#20
Pere Gascon
No abstract text is available yet for this article.
December 2012: Chinese Clinical Oncology
keyword
keyword
107123
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"